Kashiv BioSciences and CRISTÁLIA Sign Licensing and Supply Deal for Omalizumab Biosimilar in Latin America

Kashiv BioSciences, LLC has announced a licensing and supply agreement with Brazilian pharmaceutical giant CRISTÁLIA for the commercialization of ADL-018, a proposed biosimilar to Xolair (omalizumab), across Latin America.

The partnership marks a significant step in expanding access to biosimilar treatments in the region. According to IQVIA, global sales of omalizumab reached approximately $5.0 billion in 2024, with Latin America contributing around $140 million.

Under the agreement, Kashiv will handle product development within the agreed territories, while CRISTÁLIA will take charge of licensing, distribution, and commercialization efforts in the LATAM market.

“CRISTÁLIA is an ideal partner to commercialize ADL-018 across Latin America, supporting Kashiv’s mission to expand its biosimilar portfolio and increase global access,” said Dr. Sandeep Athalye, CEO of Kashiv BioSciences. “We look forward to CRISTÁLIA bringing our omalizumab biosimilar to patients in this important region.”

CRISTÁLIA’s Chairman, Dr. Ogari Castro Pacheco, echoed the enthusiasm: “We are thrilled to have entered a partnership with Kashiv for the licensing of Omalizumab biosimilars in the LATAM region. This molecule will be a key asset to our biosimilars portfolio and aligns with our strategy to expand patient access to high-quality, affordable treatments.”

The agreement further strengthens both companies’ commitment to improving healthcare access and affordability through the development and distribution of biosimilar medicines.